Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer

Metformin is currently a strong candidate anti-tumor agent in multiple cancers. However, its anti-tumor effectiveness varies among different cancers or subpopulations, potentially due to tumor heterogeneity. It thus remains unclear which hepatocellular carcinoma (HCC) patient subpopulation(s) can be...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Junru, Lu, Hui, Ma, Wenhao, Tian, Wenjing, Lu, Zhuan, Yang, Hongying, Cai, Yongping, Cai, Pengfei, Sun, Yuchen, Zhou, Zilong, Feng, Jiaqian, Deng, Jiazhong, Shu, Ying, Qu, Kun, Jia, Weidong, Gao, Ping, Zhang, Huafeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Higher Education Press 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237198/
https://www.ncbi.nlm.nih.gov/pubmed/35217990
http://dx.doi.org/10.1007/s13238-022-00906-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237198/
https://www.ncbi.nlm.nih.gov/pubmed/35217990
http://dx.doi.org/10.1007/s13238-022-00906-6

Ejemplares similares